Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.48 |
| ▸ | HTT | P42858 | 3/20 | 0.47 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | GAA | P10253 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12409575 | 1.00 | ALDH1A1 (0.52) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| Hydrochloric Acid SCHEMBL21879630 | 0.98 | ALDH1A1 (0.55) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL15599075 | 0.88 | ALDH1A1 (0.40) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL12471392 | 0.86 | ALDH1A1 (0.41) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL23665146 | 0.83 | HTT (0.49) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL11199274 | 0.83 | HTT (0.49) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL11199747 | 0.82 | SMN1; SMN2 (0.52) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL11200026 | 0.82 | SMN1; SMN2 (0.52) | ALDH1A1MAPTSMN1; SMN2HTTLMNA | |
| SCHEMBL22519413 | 0.81 | — | — | |
| SCHEMBL11107158 | 0.80 | HTT (0.51) | ALDH1A1MAPTSMN1; SMN2HTTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | claimed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | claimed |
| CN-122055805-A | Super capacitor comprising sulfur-based electrolyte system | 京瓷AVX元器件公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20250285817-A1 | Ultracapacitor for Use in a Solder Reflow Process | KYOCERA AVX Components Corporation | 2025-09-11 | — | — | US | disclosed |
| WO-2025085753-A1 | ULTRACAPACITOR INCLUDING A SULFUR-BASED ELECTROLYTE SYSTEM | KYOCERA AVX Components Corporation (US) | 2025-04-24 | — | — | WO | disclosed |
| US-20250132104-A1 | Ultracapacitor Including a Sulfur-Based Electrolyte System | KYOCERA AVX Components Corporation | 2025-04-24 | — | — | US | disclosed |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | SHY Therapeutics LLC (US) | 2023-05-18 | — | — | US | disclosed |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | SHY Therapeutics LLC (US) | 2022-01-04 | — | — | US | disclosed |
| US-9520617-B2 | Sulfolane mixtures as ambient aprotic polar solvents | ADVANCED TECHNOLOGY MATERIALS, INC. (US) | 2016-12-13 | — | — | US | disclosed |
| US-20140319423-A1 | SULFOLANE MIXTURES AS AMBIENT APROTIC POLAR SOLVENTS | ADVANCED TECHNOLOGY MATERIALS, INC (US) | 2014-10-30 | — | — | US | disclosed |
| EP-2778158-A1 | Sulfolane mixtures as ambient aprotic polar solvents | Advanced Technology Materials, Inc. (US) | 2014-09-17 | — | — | EP | disclosed |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | ASTRAZENECA AB (SE) | 2012-03-15 | — | — | US | disclosed |
| US-7332492-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2008-02-19 | — | — | US | disclosed |
| US-6967216-B2 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-11-22 | — | — | US | disclosed |
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | ASTRAZENECA AB (SE) | 2005-09-22 | — | — | US | disclosed |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | ASTRAZENECA AB (SE) | 2003-12-04 | — | — | US | disclosed |
| US-4374040-A | ANTICORROSION, ANTISCALE, ANTIDERPOSIT | BUCKMAN LABORATORIES, INC. (US) | 1983-02-15 | — | — | US | disclosed |
| US-4243524-A | ANTISCALING, ANTISLUDGING | BUCKMAN LABORATORIES, INC. (US) | 1981-01-06 | — | — | US | disclosed |
| US-4181806-A | ANTISLUDGING AGENTS, ANTISCALING AGENTS | BUCKMAN LABORATORIES, INC. (US) | 1980-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050209233-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by NP Y5 receptor | NPY5R, NPY1R, NPY2R | ALDH1A1 3658/4885MAPT 1604/4885SMN1; SMN2 1627/4885 |
| US-20120065214-A1 | COMPOUNDS AND THEIR USES 708 | CYP3A7, CYP2C8, CYP2C18 | ALDH1A1 340/4885MAPT 2316/4885SMN1; SMN2 4272/4885 |
| US-20030225097-A1 | Amino substituted dibenzothiophene derivatives for the treatment of disorders mediated by np y5 receptor | NPY5R, NPY1R, NPY2R | ALDH1A1 3792/4885MAPT 1610/4885SMN1; SMN2 1621/4885 |
| US-11213515-B1 | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease | HRAS, KRAS, NRAS | ALDH1A1 3448/4885MAPT 4169/4885SMN1; SMN2 3555/4885 |
| US-20230149369-A1 | Compounds that Interact with the Ras Superfamily for the Treatment of Cancers, Inflammatory Diseases, Rasopathies, and Fibrotic Disease | HRAS, KRAS, NRAS | ALDH1A1 3448/4885MAPT 4169/4885SMN1; SMN2 3555/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.